Weight and See: The Use and Impact of GLP-1 RAs in Obesity and Long-Term Disease Management
ACPE Number:0204-0000-25-404-H01-P Content Release Date: May 28, 2025 Expiration Date: May 28, 2026 Activity Type: Application-based CE Credits: 1.0 contact hour (0.1 CEUs) Activity Fee: Free
Activity Overview
Obesity is a serious, chronic, and progressive disease involving genetic, biological, and environmental influences. Obesity is a worldwide epidemic that impacts more than just a person’s weight. Obesity is associated with over 200 different organ complications affecting every organ system in the body. People with obesity lose years of life due to the disease and obesity-related complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide benefit in overcoming the mechanisms of obesity leading to significant weight loss, and also provide benefit combatting many of the mechanisms of obesity-associated comorbidities such as prediabetes, type 2 diabetes, metabolic dysfunction-associated fatty liver disease (MAFLD), metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea, osteoarthritis, and heart failure with preserved ejection fraction. Additionally, GLP-1 RAs have shown benefit in the reduction of major adverse cardiovascular events, atherosclerotic cardiovascular disease (ASCVD) risk reduction, various benefits throughout the body, and a reduction in morbidity and mortality in patients with obesity.
Given the serious impact of obesity and its related comorbidities, adherence to obesity medications and treating comorbidities is crucial for improving patient outcomes. Pharmacists can provide long-term, patient-centered care and positively impact patient outcomes. Pharmacists are the most accessible healthcare professionals who play a key role in obesity management, treating obesity-related comorbidities, and providing patient education on the importance of long-term disease management for reducing the risk of morbidity and mortality.
*Please note, this activity was presented live on April 23, 2025. You can only claim credit once for this activity; live or home study.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The target audience for this education is pharmacists who practice in hospitals, health systems, and ambulatory clinics who care for or are interested in the care of patients with obesity.
Jennifer N. Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, Activity Chair Clinical Professor and Director of Pharmacy Education University of South Carolina College of Pharmacy Greenville, South Carolina
Jennifer N. Clements, PharmD is a Clinical Professor and Director of Pharmacy Education with the University of South Carolina College of Pharmacy at the School of Medicine – Greenville Campus. Dr. Clements earned her Pharm.D. from Campbell University in 2006 and completed a primary care pharmacy practice residency in 2007 at the Ralph H. Johnson VA Medical Center in Charleston, South Carolina. She is a board-certified pharmacotherapy specialist, board-certified ambulatory care pharmacist, certified diabetes care and education specialist, and board certified in advanced diabetes management. Dr. Clements has authored numerous publications and presentations related to diabetes and obesity pharmacotherapy.
Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP is an Endocrinology Clinical Pharmacy Specialist. She serves as the Co-Director of Endocrine Disorders in Pregnancy and the Director of Education and Training in Diabetes Technology at the Cleveland Clinic Endocrinology and Metabolism Institute. Dr. Isaacs earned her bachelor’s degree in chemistry from the University of Illinois at Chicago, Doctor of Pharmacy Degree from Southern Illinois University Edwardsville (SIUE) and completed a pharmacy practice residency at the Philadelphia Veterans Affairs. Dr. Isaacs holds board certifications in pharmacotherapy, ambulatory care, and advanced diabetes management and is a Certified Diabetes Care and Education Specialist.
Dr. Isaacs served on the American Diabetes Association (ADA) Professional Practice Committee from 2020-2023, the committee that updates the ADA Standards of Care. She also served on the Association of Diabetes Care and Education Specialists (ADCES) Board of Directors from 2021-2024. She is currently on the leadership of the Diabetes Practice Group for the American Association of Clinical Endocrinology. She co-hosts a popular podcast titled “Diabetes Dialogue: Technology, Therapeutics and Real-World Perspectives.” She advocates access and choice to the latest technologies and therapeutics for all people with diabetes and obesity and speaks on related topics nationally and internationally. She was the ADCES Diabetes Care and Education Specialist of the Year in 2020 and inducted into the SIUE Alumni Hall of Fame in 2022 for her far reaching contributions in diabetes care.
Jeffery S. Vender, MD, MCCM, MBA is the Emeritus, Harris Family Foundation Chairman of the Department of Anesthesiology at NorthShore University Health System in Evanston, Illinois and a Clinical Professor at the University of Chicago Pritzker School Of Medicine in Chicago, Illinois. He is a past member of the NorthShore University Health System Faculty Practice Associates Board of Directors, Past Chair of the Medical Executive Committee for the Professional Staff at NorthShore and previously served on Northshore’s Board of Directors. Dr. Vender served as Chair of Anesthesia from 1990-2015 and received an appointment of adjunct Professor of Biomedical Engineering at Northwestern University. He served as the Director of the Critical Care Services at Evanston Hospital from 1987-2000 and the Interim Chairman at Northwestern University Department of Anesthesiology from July 1999 until October 2000. Dr. Vender has participated and Chaired numerous state and national committees of various medical organizations, edited several medical texts, has published over 135 articles and book chapters and has been an invited lecturer at over 250 national and international meetings on topics of anesthesiology, critical care, organizational change, and leadership. In addition, Dr. Vender serves as an editor and/or reviewer for many medical journals.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Jennifer N. Clements: Speaker’s bureau – Lilly; Novo Nordisk
Diana Isaacs: Speaker’s bureau - Dexcom; Abbott; Novo Nordisk; Lilly; Sanofi
All other persons in control of content do not have any relevant financial relationships with an ineligible company.As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.
Provided by ASHP
Supported by an educational grant from Novo Nordisk
